Leisure Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Leisure Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,164	Closed	-$22K	–	115
2017 Q3	$22K	Buy	+3,164	New	+$23.8K	0.02%	108
2017 Q1	–	Sell	-3,475	Closed	-$51K	–	105
2016 Q4	$51K	Buy	3,475 +66	+2%	+$987	0.05%	105
2016 Q3	$59K	Sell	3,409 -33	-1%	-$1.07K	0.06%	100
2016 Q2	$108K	Buy	+3,442	New	+$108K	0.11%	98
2016 Q1	–	Sell	-3,439	Closed	-$151K	–	103
2015 Q4	$151K	Buy	3,439 +85	+3%	+$3.83K	0.14%	98
2015 Q3	$142K	Buy	3,354 +125	+4%	+$6.58K	0.15%	85
2015 Q2	$148K	Buy	3,229 +184	+6%	+$8.43K	0.15%	87
2015 Q1	$120K	Sell	3,045 -5,410	-64%	-$238K	0.12%	91
2014 Q4	$221K	Buy	+8,455	New	+$269K	0.21%	76

Other funds holding ARCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Leisure Capital Management's ARCT Position: Q4 2017 in Review

Leisure Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2017, closing a stake of 3,164 shares — an estimated $22K sold.

Leisure Capital Management first reported a position in ARCT in Q4 2014 and held it in 9 quarters. The position peaked at $221K in Q4 2014. 19 funds tracked by Wall St. Rank hold ARCT as of Q4 2017.

Leisure Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2017 after selling out during the quarter.
Leisure Capital Management sold 3,164 Arcturus Therapeutics shares in Q4 2017, an estimated $22K.
Leisure Capital Management first reported a position in Arcturus Therapeutics in Q4 2014 and held it in 9 quarters.
Leisure Capital Management's Arcturus Therapeutics position peaked at $221K in Q4 2014.
19 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2017.

Based on Leisure Capital Management's 13F filing for Q4 2017, filed 12 Feb 2018.